Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for allergic fungal rhinosinusitis
jRCT2041210031Completed
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in allergic fungal rhinosinusitis (AFRS) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Change from baseline in sinus opacifications assessed by CT using the Lund-Mackay score at Week 52. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
allergic fungal rhinosinusitis (AFRS)
Beyond the preview
Go deeper on jRCT2041210031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210031.